Get the Stockscreener App
6.35
7.97%
-0.55
After Hours:
6.33
-0.02
-0.31%
Engene Holdings Inc stock is traded at $6.35, with a volume of 223.76K.
It is down -7.97% in the last 24 hours and down -15.22% over the past month.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
See More
Previous Close:
$6.90
Open:
$6.93
24h Volume:
223.76K
Relative Volume:
1.45
Market Cap:
$323.70M
Revenue:
-
Net Income/Loss:
$-103.21M
P/E Ratio:
-1.3804
EPS:
-4.6001
Net Cash Flow:
$-26.70M
1W Performance:
-10.56%
1M Performance:
-15.22%
6M Performance:
-18.06%
1Y Performance:
-18.59%
1-Day Range:
$6.06
$7.18
1-Week Range:
$6.06
$7.40
52-Week Range:
$4.42
$18.40
Engene Holdings Inc Stock (ENGN) Company Profile
Name
Engene Holdings Inc
Sector
Industry
Phone
(514) 332-4888
Address
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Holdings Inc
|
6.35 | 323.70M | 0 | -103.21M | -26.70M | -4.6001 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Initiated | H.C. Wainwright | Buy |
| Nov-27-24 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Apr-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Mar-28-24 | Initiated | UBS | Buy |
| Mar-08-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | Leerink Partners | Outperform |
View All
Engene Holdings Inc Stock (ENGN) Latest News
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Where are the Opportunities in (ENGN) - Stock Traders Daily
ENGNenGene Holdings Inc. Latest Stock News & Market Updates - StockTitan
Revolutionary Non-Viral Bladder Cancer Therapy Shows Promise: Key Data Coming at ASCO GU - StockTitan
FY2026 EPS Estimates for enGene Boosted by Leerink Partnrs - Defense World
enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of “Buy” from Analysts - Defense World
enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Leerink Partnrs Brokers Lift Earnings Estimates for enGene - MarketBeat
FY2029 EPS Estimates for enGene Reduced by Leerink Partnrs - MarketBeat
enGene Announces Oversubscribed $200 Million Private Placement F - GuruFocus.com
(ENGN) Proactive Strategies - Stock Traders Daily
Insider Returns Down To US$14k As enGene Holdings' Stock Dips 11% - Simply Wall St
How Much Upside is Left in enGene Holdings Inc. (ENGN)? Wall Street Analysts Think 238.77% - MSN
(ENGN) Trading Report - Stock Traders Daily
enGene Holdings Inc. (ENGN) Upgraded to Strong Buy: Here's Why - MSN
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of “Buy” by Analysts - Defense World
(ENGN) Technical Pivots with Risk Controls - Stock Traders Daily
enGene Holdings Awards Stock Options to New Employees in Key Talent Acquisition Move - StockTitan
enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Down 93.4% in December - MarketBeat
Engene Holdings Faces Regulatory Challenges and Business Risks Amid Clinical Trial Hurdles - MSN
HC Wainwright Forecasts enGene’s Q1 Earnings (NASDAQ:ENGN) - Defense World
What is HC Wainwright's Estimate for enGene Q1 Earnings? - MarketBeat
Engene shares initiated at Buy as promising detalimogene data positions it ahead of recent approvals - Investing.com Nigeria
enGene (NASDAQ:ENGN) Receives “Market Outperform” Rating from JMP Securities - Defense World
enGene (NASDAQ:ENGN) Now Covered by Analysts at HC Wainwright - Defense World
enGene (NASDAQ:ENGN) Receives Market Outperform Rating from JMP Securities - MarketBeat
enGene (NASDAQ:ENGN) Now Covered by HC Wainwright - MarketBeat
Franklin Resources Inc. Buys 389,918 Shares of enGene Holdings Inc. (NASDAQ:ENGN) - MarketBeat
enGene Holdings inks $100M share sale deal with Jefferies - Investing.com
EnGene : Material Agreement Form 8 K - Marketscreener.com
Form 424B5 enGene Holdings Inc. - StreetInsider.com
EnGene Holdings Inc. Reports Earnings Results for the Full Year Ended October 31, 2024 - Marketscreener.com
enGene Reports Full Year 2024 Financial Results and Provides a Business Update - BioSpace
enGene Holdings Inc. (ENGN) reports earnings - Quartz
enGene (NASDAQ:ENGN) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
enGene Holdings: Compelling Early Data Bode Well For Their Near-Term Outlook (NASDAQ:ENGN) - Seeking Alpha
Here's Why enGene Holdings Inc. (ENGN) is Poised for a Turnaround After Losing -16.9% in 4 Weeks - MSN
(ENGN) Investment Analysis - Stock Traders Daily
Engene Holdings Inc Stock (ENGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):